Alemtuzumab in the Treatment of Multiple Sclerosis

Oh, Jeeyoung

J Mult Scler > Volume 7(2); 2016 > Article

Review Article

Journal of Multiple Sclerosis 2016;7(2):49-54.
Published online September 1, 2016.

다발성경화증에서 알렘투주맙 치료

오지영

건국대학교병원

Alemtuzumab in the Treatment of Multiple Sclerosis

Jeeyoung Oh

Department of Neurology, Konkuk University Medical Center, Seoul, Korea

Abstract

"Alemtuzumab is a humanized monoclonal antibody against CD52 and is recently approved for the second-line therapy of active relapse-remitting multiple sclerosis in Korea. Alemtuzumab leads to arapid and long-lasting depletion of peripheral T and B cells with repopulation of immune cell compositionresulting in the rebalancing of immune-tolerance network. However, it has a considerable adverseeffects including infusion associated reaction, infection, and secondary autoimmune diseaserequiring close and regular monitoring during and for 4 years after the final infusion cycle. This reviewwill provide a summary of mechanism of action, data from the pivotal clinical studies, and safetyprofiles of alemtuzumab. Journal of Multiple Sclerosis 7(2):49-54, 2016"

Key Words: Alemtuzumab, CD52, Monoclonal antibody, Multiple sclerosis